Table 2.
Clinical trials of AMP administration in infectious diseases.
| Phase | AMP type | Pathologic condition | Route of administration | Primary Purpose | NCT number |
|---|---|---|---|---|---|
| 1 | TAPS-18 | Periodontitis | Topical | Treatment | NCT05125718 |
| 2 | C16G2 | Dental Caries | Topical | Prevention | NCT02509845 |
| C16G2 | Dental Caries | Topical | Treatment | NCT03004365 | |
| MBI 226 | Acne Vulgaris | Topical | Treatment | NCT00211523 | |
| C16G2 | Dental Caries | Topical | Treatment | NCT03196219 | |
| C16G2 | Dental Caries | Topical | Prevention | NCT02254993 | |
| C16G2 | Dental Caries | Topical | Treatment | NCT02594254 | |
| NVXT | Onychomycosis | Topical | Treatment | NCT02933879 | |
| PAC113 | Oral Candidiasis | Topical | Treatment | NCT00659971 | |
| Dalbavancin | Osteomyelitis | Intravenous | Treatment | NCT02685033 | |
| Brilacidin | Skin Infections | Topical | Treatment | NCT02052388 | |
| AB103 | Necrotizing Soft Tissue Infections | Topical | Treatment | NCT01417780 | |
| 3 | Pexiganan | Diabetic Foot Infection | Topical | Treatment | NCT01594762 |
| CB-183,315 | Clostridium difficile Infection | Oral | Treatment | NCT01597505 |